Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl.

The aim of this study was to design stable parenteral pharmaceutical final products containing 25 mg and 50 mg ES-285.HCl per dosage unit for use in phase I clinical trials. ES-285.